Efficacy and Safety of Topical Chloroquine in Mild to Moderate Dry Eye Disease

References

• Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83. doi:10.1016/j.jtos.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Wei Y, Asbell PA. The core mechanism of Dry Eye Disease (DED) is inflammation. Eye Contact Lens. 2014;40(4):248–56. doi:10.1097/ICL.0000000000000042.
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14:S88–101.
   PubMed Web of Science ®Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999;106(4):811–16. doi:10.1016/S0161-6420(99)90171-9.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Cs a phase 3 study group. Ophthalmology. 2000;107(4):631–39. Erratum in: Ophthalmology 2000;107(7):1220. doi:10.1016/S0161-6420(99)00176-1.
   PubMed Web of Science ®Google Scholar
• Perry HD, Solomon R, Donnenfeld ED, Perry AR, Wittpenn JR, Greenman HE, Savage HE. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126(8):1046–50. doi:10.1001/archopht.126.8.1046.
   PubMedGoogle Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, D’Ambrosio FA Jr, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP. OPUS-1 study group. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121:475–83.
   PubMed Web of Science ®Google Scholar
• Epitropoulos AT, Donnenfeld ED, Shah ZA, Holland EJ, Gross M, Faulkner WJ, Matossian C, Lane SS, Toyos M, Bucci FA Jr, et al. Effect of oral re-esterified omega-3 nutritional supplementation on dry eyes. Cornea. 2016;35(9):1185–91. doi:10.1097/ICO.0000000000000801.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337–42. Review. doi:10.1016/j.ajo.2003.11.009.
   PubMed Web of Science ®Google Scholar
• Iii WHR, Karsolia A. New drugs for the treatment of dry eye disease. Clin Optometry. 2015;2015(7):91–102. doi:10.2147/OPTO.S68271.
   Web of Science ®Google Scholar
• Yavuz S, Asfuroğlu E, Bicakcigil M, Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndrome. Rheumatol Int. 2011;31(8):1045–49. doi:10.1007/s00296-010-1415-4.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. American academy of ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386–94. doi:10.1016/j.ophtha.2016.01.058.
   PubMed Web of Science ®Google Scholar
• Bhavsar AS, Bhavsar SG, Jain SM. Evaluation of the effects of chloroquine phosphate eye drops in patients with dry eye syndrome. Int J Biomed Adv Res. 2011;2(6):198–214. doi:10.7439/ijbar.v2i6.34.
   Google Scholar
• Methodologies to diagnose and monitor dry eye disease: report of the diagnostic methodology subcommittee of the international dry eye workshop (2007). Ocul Surf. 2007;5(2):108–52. Review. doi:10.1016/S1542-0124(12)70083-6.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson M, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the ocular surface disease index. Arch Ophthalmol. 2000;118(5):615–21. doi:10.1001/archopht.118.5.615.
   PubMedGoogle Scholar
• Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016;25(3):1057–73. doi:10.1177/0962280215588241.
   PubMed Web of Science ®Google Scholar
• Fenner BJ, Tong L. Corneal staining characteristics in limited zones compared with whole cornea documentation for the detection of dry eye subtypes. Invest Ophth Vis Sci. 2013;54(13):8013–19. doi:10.1167/iovs.13-12802.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J Off Publ Contact Lens Assoc Ophthalmol Inc. 1995;21:221–32.
   Google Scholar
• van Bijsterveld OP. Diagnostic tests in the sicca syndrome. Arch Ophthalmol. 1969;82(1):10–14. doi:10.1001/archopht.1969.00990020012003.
   PubMedGoogle Scholar
• Nelson JD, Havener VR, Cameron JD. Cellulose acetate impressions of the ocular surface. Dry eye states. Arch Ophthalmol Chic IL 1960. 1983;101(12):1869–72. doi:10.1001/archopht.1983.01040020871007.
   PubMedGoogle Scholar
• Nelson JD. Impression cytology. Cornea. 1988;7(1):71–81. doi:10.1097/00003226-198801000-00012.
   PubMed Web of Science ®Google Scholar
• Thomé R, Lopes SCP, Costa FTM, Verinaud L. Chloroquine: modes of action of an undervalued drug. Immunol Lett. 2013;153(1–2):50–57. doi:10.1016/j.imlet.2013.07.004.
   PubMed Web of Science ®Google Scholar
• van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24:55–60.
   PubMed Web of Science ®Google Scholar
• Shivakumar S, Panigrahi T, Shetty R, Subramani M, Ghosh A, Jeyabalan N. Chloroquine protects human corneal epithelial cells from desiccation stress induced inflammation without altering the autophagy flux. Biomed Res Int. 2018;2018:1–13. doi:10.1155/2018/7627329.
   Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol Chic IL 1960. 2002;120:330–37.
   PubMed Web of Science ®Google Scholar
• Barbosa FL, Xiao Y, Bian F, Coursey TG, Ko BY, Clevers H, de Paiva CS, Pflugfelder SC. Goblet cells contribute to ocular surface immune tolerance—implications for dry eye disease. Int J Mol Sci. 2017;18(5). doi:10.3390/ijms18050978.
   Web of Science ®Google Scholar
• Gipson IK. Goblet cells of the conjunctiva: a review of recent findings. Prog Retin Eye Res. 2016;54:49–63. doi:10.1016/j.preteyeres.2016.04.005.
   PubMed Web of Science ®Google Scholar
• Ma X, He L, He D, Xu J. Chloroquine keratopathy of rheumatoid arthritis patients detected by in vivo confocal microscopy. Curr Eye Res. 2012;37(4):293–99. doi:10.3109/02713683.2011.631719.
   PubMed Web of Science ®Google Scholar
• Yamagiwa Y, Haranosono Y, Nemoto S, Atsumi I, Kurata M, Kito G, Hatakeyama H, Koizumi H, Sakaki H. Characteristics of corneal phospholipidosis induced by topical ocular application of chloroquine and amiodarone in rabbits. J Toxicol Pathol. 2017;30(2):135–43. doi:10.1293/tox.2016–0003.
   PubMed Web of Science ®Google Scholar